Explore the full insider trade history of 에이프릴바이오, a listed equity based in South Korea. Shares are quoted on KR KR, under the oversight of DART (FSS). Operating in the Healthcare sector, 에이프릴바이오 has published 4 insider filings. Market capitalisation: €1,224.3bn. The latest transaction was disclosed on 16 April 2026 — Purchase. Among the most active insiders: 서상준. All data is accessible without an account.